...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Response to Koo's Zenith post on RVX
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Actually I think it is the company’s responsibility to update their info. RVX still has Mar 15, 2018 as the anticipated start date for the study with those on hemodialysis. I think they missed it.......

4 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply